2 results
Approved WMOCompleted
The primary objective of the study is to determine whether the optimal atrioventricular delay and interventricular delay in cardiac resynchronization therapy are a function of exercise. Secondary objectives are the development of an automatic…
Approved WMOCompleted
Lu AF28996 is an orally administered investigational compound of a potent, long-acting dopamine agonist, Lu AA40326, currently under development by H. Lundbeck A/S for the treatment of Parkinson*s disease (PD). Primary Objective:to investigate the…